Michelle L James1, Nadia P Belichenko2, Thuy-Vi V Nguyen2, Lauren E Andrews3, Zhaoqing Ding4, Hongguang Liu3, Deepika Bodapati3, Natasha Arksey3, Bin Shen3, Zhen Cheng3, Tony Wyss-Coray4, Sanjiv S Gambhir3, Frank M Longo2, Frederick T Chin5. 1. Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California Department of Neurology and Neurological Sciences, Stanford University, Stanford, California; and. 2. Department of Neurology and Neurological Sciences, Stanford University, Stanford, California; and. 3. Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California. 4. Department of Neurology and Neurological Sciences, Stanford University, Stanford, California; and Veterans Administration Palo Alto Health Care System, Palo Alto, California. 5. Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, California chinf@stanford.edu.
Abstract
UNLABELLED: Herein we aimed to evaluate the utility of N-(2,5-dimethoxybenzyl)-2-(18)F-fluoro-N-(2-phenoxyphenyl)acetamide ((18)F-PBR06) for detecting alterations in translocator protein (TSPO) (18 kDa), a biomarker of microglial activation, in a mouse model of Alzheimer's disease (AD). METHODS: Wild-type (wt) and AD mice (i.e., APP(L/S)) underwent (18)F-PBR06 PET imaging at predetermined time points between the ages of 5-6 and 15-16 mo. MR images were fused with PET/CT data to quantify (18)F-PBR06 uptake in the hippocampus and cortex. Ex vivo autoradiography and TSPO/CD68 immunostaining were also performed using brain tissue from these mice. RESULTS: PET images showed significantly higher accumulation of (18)F-PBR06 in the cortex and hippocampus of 15- to 16-mo-old APP(L/S) mice than age-matched wts (cortex/muscle: 2.43 ± 0.19 vs. 1.55 ± 0.15, P < 0.005; hippocampus/muscle: 2.41 ± 0.13 vs. 1.55 ± 0.12, P < 0.005). And although no significant difference was found between wt and APP(L/S) mice aged 9-10 mo or less using PET (P = 0.64), we were able to visualize and quantify a significant difference in (18)F-PBR06 uptake in these mice using autoradiography (cortex/striatum: 1.13 ± 0.04 vs. 0.96 ± 0.01, P < 0.05; hippocampus/striatum: 1.266 ± 0.003 vs. 1.096 ± 0.017, P < 0.001). PET results for 15- to 16-mo-old mice correlated well with autoradiography and immunostaining (i.e., increased (18)F-PBR06 uptake in brain regions containing elevated CD68 and TSPO staining in APP(L/S) mice, compared with wts). CONCLUSION: (18)F-PBR06 shows great potential as a tool for visualizing TSPO/microglia in the progression and treatment of AD.
UNLABELLED: Herein we aimed to evaluate the utility of N-(2,5-dimethoxybenzyl)-2-(18)F-fluoro-N-(2-phenoxyphenyl)acetamide ((18)F-PBR06) for detecting alterations in translocator protein (TSPO) (18 kDa), a biomarker of microglial activation, in a mouse model of Alzheimer's disease (AD). METHODS: Wild-type (wt) and ADmice (i.e., APP(L/S)) underwent (18)F-PBR06 PET imaging at predetermined time points between the ages of 5-6 and 15-16 mo. MR images were fused with PET/CT data to quantify (18)F-PBR06 uptake in the hippocampus and cortex. Ex vivo autoradiography and TSPO/CD68 immunostaining were also performed using brain tissue from these mice. RESULTS: PET images showed significantly higher accumulation of (18)F-PBR06 in the cortex and hippocampus of 15- to 16-mo-old APP(L/S) mice than age-matched wts (cortex/muscle: 2.43 ± 0.19 vs. 1.55 ± 0.15, P < 0.005; hippocampus/muscle: 2.41 ± 0.13 vs. 1.55 ± 0.12, P < 0.005). And although no significant difference was found between wt and APP(L/S) mice aged 9-10 mo or less using PET (P = 0.64), we were able to visualize and quantify a significant difference in (18)F-PBR06 uptake in these mice using autoradiography (cortex/striatum: 1.13 ± 0.04 vs. 0.96 ± 0.01, P < 0.05; hippocampus/striatum: 1.266 ± 0.003 vs. 1.096 ± 0.017, P < 0.001). PET results for 15- to 16-mo-old mice correlated well with autoradiography and immunostaining (i.e., increased (18)F-PBR06 uptake in brain regions containing elevated CD68 and TSPO staining in APP(L/S) mice, compared with wts). CONCLUSION: (18)F-PBR06 shows great potential as a tool for visualizing TSPO/microglia in the progression and treatment of AD.
Authors: Frederick M Lartey; G-One Ahn; Bin Shen; Keith-Travis Cord; Tenille Smith; Joshua Y Chua; Sahar Rosenblum; Hongguang Liu; Michelle L James; Sophia Chernikova; Star W Lee; Laura J Pisani; Rabindra Tirouvanziam; John W Chen; Theo D Palmer; Frederick T Chin; Raphael Guzman; Edward E Graves; Billy W Loo Journal: Mol Imaging Biol Date: 2013-07-09 Impact factor: 3.488
Authors: Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman Journal: Cold Spring Harb Perspect Med Date: 2011-09 Impact factor: 6.915
Authors: M Filippi; F Agosta; G B Frisoni; N De Stefano; A Bizzi; M Bozzali; A Falini; M A Rocca; S Sorbi; C Caltagirone; G Tedeschi Journal: Curr Alzheimer Res Date: 2012-12 Impact factor: 3.498
Authors: Yota Fujimura; Yasuyuki Kimura; Fabrice G Siméon; Leah P Dickstein; Victor W Pike; Robert B Innis; Masahiro Fujita Journal: J Nucl Med Date: 2009-12-15 Impact factor: 10.057
Authors: Michelle L James; Bin Shen; Cristina L Zavaleta; Carsten H Nielsen; Christophe Mesangeau; Pradeep K Vuppala; Carmel Chan; Bonnie A Avery; James A Fishback; Rae R Matsumoto; Sanjiv S Gambhir; Christopher R McCurdy; Frederick T Chin Journal: J Med Chem Date: 2012-09-20 Impact factor: 7.446
Authors: Jatta S Takkinen; Francisco R López-Picón; Rana Al Majidi; Olli Eskola; Anna Krzyczmonik; Thomas Keller; Eliisa Löyttyniemi; Olof Solin; Juha O Rinne; Merja Haaparanta-Solin Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200
Authors: Vera Russmann; Matthias Brendel; Erik Mille; Angela Helm-Vicidomini; Roswitha Beck; Lisa Günther; Simon Lindner; Axel Rominger; Michael Keck; Josephine D Salvamoser; Nathalie L Albert; Peter Bartenstein; Heidrun Potschka Journal: Neuroimage Clin Date: 2017-04-05 Impact factor: 4.881
Authors: Michelle L James; Nadia P Belichenko; Adam J Shuhendler; Aileen Hoehne; Lauren E Andrews; Christina Condon; Thuy-Vi V Nguyen; Vladimer Reiser; Paul Jones; William Trigg; Jianghong Rao; Sanjiv S Gambhir; Frank M Longo Journal: Theranostics Date: 2017-03-24 Impact factor: 11.556
Authors: Bin Liu; Kevin X Le; Mi-Ae Park; Shuyan Wang; Anthony P Belanger; Shipra Dubey; Jeffrey L Frost; Peter Holton; Vladimir Reiser; Paul A Jones; William Trigg; Marcelo F Di Carli; Cynthia A Lemere Journal: J Neurosci Date: 2015-11-25 Impact factor: 6.167